Pro Vise Management Group, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Pro Vise Management Group, LLC
- $1.25 Billion
- Q3 2024
Shares
2 transactions
Others Institutions Holding CPRX
# of Institutions
332Shares Held
94.7MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$448 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$193 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$149 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$136 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$72.3 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.46B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...